APA (7th ed.) Citation

T, D., AL, B., LI, G., GU, H., HR, M., I, L., . . . SB, H. (2023). Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nature medicine, 29(11), 2955. https://doi.org/10.1038/s41591-022-02076-8

Chicago Style (17th ed.) Citation

T, Dam, et al. "Author Correction: Safety and Efficacy of Anti-tau Monoclonal Antibody Gosuranemab in Progressive Supranuclear Palsy: A Phase 2, Randomized, Placebo-controlled Trial." Nature Medicine 29, no. 11 (2023): 2955. https://doi.org/10.1038/s41591-022-02076-8.

MLA (9th ed.) Citation

T, Dam, et al. "Author Correction: Safety and Efficacy of Anti-tau Monoclonal Antibody Gosuranemab in Progressive Supranuclear Palsy: A Phase 2, Randomized, Placebo-controlled Trial." Nature Medicine, vol. 29, no. 11, 2023, p. 2955, https://doi.org/10.1038/s41591-022-02076-8.